Study analysis · Journal of the American College of Cardiology · 2025
Intensive blood pressure control may benefit even the frailest patients, but at a cost to kidney health, according to a new analysis of 11,255 high-risk hypertensive adults.
Lowering systolic blood pressure below 120 mm Hg reduces heart attacks and death regardless of frailty, but may increase kidney problems in frail patients.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study looked at whether lowering blood pressure very tightly helps older, sicker people — and it found that it probably does, even if they're very frail. But it didn't test this on purpose; it just looked back at data from a different study, so we can't be 100% sure it's the treatment that caused the benefit.
What’s the bottom line?
Researchers studied 11,255 people with high blood pressure and high heart risk. They grouped them by frailty level. Some got intensive treatment aiming for systolic blood pressure below 120; others got standard treatment aiming below 140. They compared heart events, death, kidney problems, and side effects.
How strong is this study?
The original study was well-designed — people were randomly assigned to different treatments, which is the gold standard. But this part of the study just dug into the data after the fact, so while the results are promising, we have to be a little more careful trusting them than if they had planned this test from the start.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
56 / 100
- Randomizationnot randomized
- Blindingnot blinded
- Control group+15/15
- Sample size (n=11255)+20/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 567 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design can establish causation. This study is a post hoc analysis of a randomized controlled trial, so the original randomization and treatment assignment provide a strong basis for causal inference. However, because it is a secondary analysis, there is potential for selection bias and confounding by unmeasured factors within subgroups, which slightly limits the strength of causal claims compared to the primary analysis.
No Conflicts
No conflicts of interest identified
No conflicts of interest were disclosed, and the study appears to be independently conducted with no evidence of industry influence on design, analysis, or publication.
Funders
Independent Analysis Safeguards
- Central adjudication of events by a clinical event committee
- Use of standardized frailty index calculation based on established Rockwood approach
- Statistical analysis performed using established methods with imputation for missing data
The study is a post hoc analysis of the ESPRIT trial, which was funded by public Chinese institutions. No author affiliations with industry or financial ties to pharmaceutical companies are mentioned. The absence of a formal COI statement does not imply undisclosed conflicts, but no evidence of industry influence was found in the text.
Key takeaways
- 01
Intensive treatment lowered the relative risk of major heart events by about 14% to 17% across frailty groups (RR 0.83 to 0.86).
- 02
In severely frail people, the relative risk of death was 22% lower (RR 0.78), with an absolute risk reduction of about 2.6 percentage points.
- 03
Kidney composite risk was higher in moderately frail (RR 1.77; absolute increase 1.33 percentage points) and severely frail (RR 1.82; absolute increase 2.02 percentage points).
- 04
For severely frail people, intensive blood pressure control meant about 2.6 fewer deaths per 100 people over the study follow-up (absolute), but about 2 more kidney composite events per 100 people (absolute increase 2.02 percentage points).
- 05
The study did not report baseline absolute risks for all outcomes, so these absolute differences come from the reported absolute risk reductions/increases.
- 06
Side effects like fainting, falls, and acute kidney injury did not differ significantly by frailty.
Surprising findings
- Intensive BP control reduced cardiovascular events and death consistently across frailty levels, including severely frail patients.Contradicts common belief that frail patients may not benefit or may be harmed by intensive BP lowering.
- No significant increase in serious adverse events like falls, syncope, or hypotension with intensive BP control in frail patients.Clinicians often worry about these events in frail elderly, but the study found no significant difference.
- Kidney composite outcome risk increased with intensive BP control in moderately and severely frail patients.While cardiovascular benefits are clear, the kidney risk was elevated, which might offset some benefits.
Practical takeaways
For frail hypertensive patients, consider intensive BP control (<120 mm Hg) but titrate medications slowly and monitor kidney function closely.
This is a post hoc analysis; individualize based on patient preferences and comorbidities.
Medium confidenceDon't withhold intensive BP control solely based on frailty; the cardiovascular and mortality benefits appear consistent.
Ensure close monitoring for kidney function decline, especially in those with chronic kidney disease.
Medium confidenceWhy this study matters
Benefits Consistent Across Frailty
In the ESPRIT trial, intensive BP control (<120 mm Hg) reduced the relative risk of major cardiovascular events by 14-17% compared to standard (<140 mm Hg). The effect was consistent across frailty groups: nonfrail RR 0.84 (95% CI 0.65-1.08), moderately frail RR 0.83 (0.70-0.99), severely frail RR 0.86 (0.69-1.08); P interaction = 0.67.
Many guidelines recommend less aggressive BP targets for frail patients, but this study suggests they benefit just as much in relative terms.
Kidney Risk in Frail Patients
While cardiovascular benefits were consistent, the risk of a composite kidney outcome increased with intensive BP control in moderately frail (RR 1.77; absolute increase 1.33%) and severely frail (RR 1.82; absolute increase 2.02%) patients. No significant increase in nonfrail.
This highlights a trade-off: intensive BP control helps the heart but may harm the kidneys in frail patients.
Serious Adverse Events Not Increased
Despite concerns, serious adverse events like hypotension, syncope, and injurious falls did not differ significantly between intensive and standard treatment across frailty groups (all interaction P > 0.05).
Common fear is that intensive BP control causes falls and fainting in frail elderly, but this study found no significant increase.
Frail Patients Achieve Target, Just Slower
Severely frail patients achieved similar long-term systolic BP (mean 119.4 mm Hg) as nonfrail (118.4 mm Hg) in the intensive arm, but target attainment at 12 months was lower: 62.4% vs 74.1%. They required slower titration.
It's possible to get frail patients to target, but it takes patience and careful monitoring.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Researchers studied 11,255 people with high blood pressure and high heart risk. They grouped them by frailty level. Some got intensive treatment aiming for systolic blood pressure below 120; others got standard treatment aiming below 140. They compared heart events, death, kidney problems, and side effects.
Research results
Intensive treatment lowered the relative risk of major heart events by about 14% to 17% across frailty groups (RR 0.83 to 0.86). In severely frail people, the relative risk of death was 22% lower (RR 0.78), with an absolute risk reduction of about 2.6 percentage points. Kidney composite risk was higher in moderately frail (RR 1.77; absolute increase 1.33 percentage points) and severely frail (RR 1.82; absolute increase 2.02 percentage points).
What this means - more context
For severely frail people, intensive blood pressure control meant about 2.6 fewer deaths per 100 people over the study follow-up (absolute), but about 2 more kidney composite events per 100 people (absolute increase 2.02 percentage points). The study did not report baseline absolute risks for all outcomes, so these absolute differences come from the reported absolute risk reductions/increases. Side effects like fainting, falls, and acute kidney injury did not differ significantly by frailty.
To characterize the benefit-harm profile of intensive blood pressure control by frailty status in a post hoc analysis of the ESPRIT randomized trial.
In 11,255 high-risk hypertensive adults, intensive systolic BP target <120 mm Hg vs standard <140 mm Hg reduced major adverse cardiovascular events (MACE) with similar relative effects across frailty groups: nonfrail RR 0.84 (95% CI 0.65-1.08), moderately frail RR 0.83 (0.70-0.99), severely frail RR 0.86 (0.69-1.08); P interaction 0.67. All-cause death showed a similar pattern; severely frail RR 0.78 (0.52-1.16), absolute risk reduction about 2.6 percentage points (95% CI 0.1-5.1 percentage points). Composite kidney outcome was increased in moderately frail RR 1.77 (absolute increase 1.33 percentage points) and severely frail RR 1.82 (absolute increase 2.02 percentage points). Serious adverse events did not differ significantly by frailty status.
Methods Used
Post hoc analysis of the multicenter, open-label ESPRIT randomized controlled trial. Participants (n=11,255; mean age 64.6 years) were categorized by Rockwood cumulative deficit frailty index: nonfrail (FI ≤0.210; 38.8%), moderately frail (FI 0.211-0.310; 46.7%), and severely frail (FI ≥0.311; 14.5%). Outcomes included MACE, all-cause death, kidney outcomes, and serious adverse events. Cox proportional hazards and modified Poisson models assessed treatment effects and interaction by frailty status.
Main Finding
Intensive systolic BP lowering to <120 mm Hg reduced the relative risk of MACE by about 14% to 17% compared with standard <140 mm Hg, with no statistically significant difference across frailty levels (nonfrail RR 0.84; moderately frail RR 0.83; severely frail RR 0.86; P interaction 0.67). For all-cause death, severely frail adults had RR 0.78 (95% CI 0.52-1.16) and an absolute risk reduction of about 2.6 percentage points (95% CI 0.1-5.1 percentage points lower). Composite kidney outcome was increased in moderately frail (RR 1.77; absolute increase 1.33 percentage points) and severely frail (RR 1.82; absolute increase 2.02 percentage points). Overall serious adverse events did not differ significantly by frailty status.
Confidence Level
Moderate. Large randomized trial sample and consistent sensitivity analyses, but this is a post hoc, hypothesis-generating analysis; safety event counts were small and most comparisons were not adjusted for multiplicity. No retraction or corrections noted.
Study Flags
Red Flags
- •Post hoc, hypothesis-generating analysis; findings are exploratory and random error cannot be excluded
- •Safety event counts were very small, making subgroup safety comparisons imprecise
- •Frailty index relied mainly on cardiometabolic variables and may reflect cardiovascular risk rather than the full spectrum of geriatric frailty
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
Intensive BP control reduced cardiovascular events and death consistently across frailty levels, including severely frail patients.
Contradicts common belief that frail patients may not benefit or may be harmed by intensive BP lowering.
Practical Takeaways
For frail hypertensive patients, consider intensive BP control (<120 mm Hg) but titrate medications slowly and monitor kidney function closely.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 567 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study looked at whether lowering blood pressure very tightly helps older, sicker people — and it found that it probably does, even if they're very frail. But it didn't test this on purpose; it just looked back at data from a different study, so we can't be 100% sure it's the treatment that caused the benefit.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Based on a large, well-conducted RCT (ESPRIT) with randomization and centralized outcome adjudication
- Large sample size (n=11,255) with detailed subgroup analysis
- Use of validated frailty index (Rockwood cumulative deficit approach)
Weaknesses
- Post hoc analysis — not pre-specified in the original trial protocol
- Potential for residual confounding despite adjustments
- Frailty index heavily weighted toward cardiometabolic deficits, possibly inflating frailty scores
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Researchers studied 11,255 people with high blood pressure and high heart risk. They grouped them by frailty level. Some got intensive treatment aiming for systolic blood pressure below 120; others got standard treatment aiming below 140. They compared heart events, death, kidney problems, and side effects.
Research results
Intensive treatment lowered the relative risk of major heart events by about 14% to 17% across frailty groups (RR 0.83 to 0.86). In severely frail people, the relative risk of death was 22% lower (RR 0.78), with an absolute risk reduction of about 2.6 percentage points. Kidney composite risk was higher in moderately frail (RR 1.77; absolute increase 1.33 percentage points) and severely frail (RR 1.82; absolute increase 2.02 percentage points).
What this means - more context
For severely frail people, intensive blood pressure control meant about 2.6 fewer deaths per 100 people over the study follow-up (absolute), but about 2 more kidney composite events per 100 people (absolute increase 2.02 percentage points). The study did not report baseline absolute risks for all outcomes, so these absolute differences come from the reported absolute risk reductions/increases. Side effects like fainting, falls, and acute kidney injury did not differ significantly by frailty.
To characterize the benefit-harm profile of intensive blood pressure control by frailty status in a post hoc analysis of the ESPRIT randomized trial.
In 11,255 high-risk hypertensive adults, intensive systolic BP target <120 mm Hg vs standard <140 mm Hg reduced major adverse cardiovascular events (MACE) with similar relative effects across frailty groups: nonfrail RR 0.84 (95% CI 0.65-1.08), moderately frail RR 0.83 (0.70-0.99), severely frail RR 0.86 (0.69-1.08); P interaction 0.67. All-cause death showed a similar pattern; severely frail RR 0.78 (0.52-1.16), absolute risk reduction about 2.6 percentage points (95% CI 0.1-5.1 percentage points). Composite kidney outcome was increased in moderately frail RR 1.77 (absolute increase 1.33 percentage points) and severely frail RR 1.82 (absolute increase 2.02 percentage points). Serious adverse events did not differ significantly by frailty status.
Methods Used
Post hoc analysis of the multicenter, open-label ESPRIT randomized controlled trial. Participants (n=11,255; mean age 64.6 years) were categorized by Rockwood cumulative deficit frailty index: nonfrail (FI ≤0.210; 38.8%), moderately frail (FI 0.211-0.310; 46.7%), and severely frail (FI ≥0.311; 14.5%). Outcomes included MACE, all-cause death, kidney outcomes, and serious adverse events. Cox proportional hazards and modified Poisson models assessed treatment effects and interaction by frailty status.
Main Finding
Intensive systolic BP lowering to <120 mm Hg reduced the relative risk of MACE by about 14% to 17% compared with standard <140 mm Hg, with no statistically significant difference across frailty levels (nonfrail RR 0.84; moderately frail RR 0.83; severely frail RR 0.86; P interaction 0.67). For all-cause death, severely frail adults had RR 0.78 (95% CI 0.52-1.16) and an absolute risk reduction of about 2.6 percentage points (95% CI 0.1-5.1 percentage points lower). Composite kidney outcome was increased in moderately frail (RR 1.77; absolute increase 1.33 percentage points) and severely frail (RR 1.82; absolute increase 2.02 percentage points). Overall serious adverse events did not differ significantly by frailty status.
Confidence Level
Moderate. Large randomized trial sample and consistent sensitivity analyses, but this is a post hoc, hypothesis-generating analysis; safety event counts were small and most comparisons were not adjusted for multiplicity. No retraction or corrections noted.
Study Flags
Red Flags
- •Post hoc, hypothesis-generating analysis; findings are exploratory and random error cannot be excluded
- •Safety event counts were very small, making subgroup safety comparisons imprecise
- •Frailty index relied mainly on cardiometabolic variables and may reflect cardiovascular risk rather than the full spectrum of geriatric frailty
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
Intensive BP control reduced cardiovascular events and death consistently across frailty levels, including severely frail patients.
Contradicts common belief that frail patients may not benefit or may be harmed by intensive BP lowering.
Practical Takeaways
For frail hypertensive patients, consider intensive BP control (<120 mm Hg) but titrate medications slowly and monitor kidney function closely.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 567 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study looked at whether lowering blood pressure very tightly helps older, sicker people — and it found that it probably does, even if they're very frail. But it didn't test this on purpose; it just looked back at data from a different study, so we can't be 100% sure it's the treatment that caused the benefit.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Based on a large, well-conducted RCT (ESPRIT) with randomization and centralized outcome adjudication
- Large sample size (n=11,255) with detailed subgroup analysis
- Use of validated frailty index (Rockwood cumulative deficit approach)
Weaknesses
- Post hoc analysis — not pre-specified in the original trial protocol
- Potential for residual confounding despite adjustments
- Frailty index heavily weighted toward cardiometabolic deficits, possibly inflating frailty scores
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The original study was well-designed — people were randomly assigned to different treatments, which is the gold standard. But this part of the study just dug into the data after the fact, so while the results are promising, we have to be a little more careful trusting them than if they had planned this test from the start.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
56 / 100
- Randomizationnot randomized
- Blindingnot blinded
- Control group+15/15
- Sample size (n=11255)+20/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 567 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design can establish causation. This study is a post hoc analysis of a randomized controlled trial, so the original randomization and treatment assignment provide a strong basis for causal inference. However, because it is a secondary analysis, there is potential for selection bias and confounding by unmeasured factors within subgroups, which slightly limits the strength of causal claims compared to the primary analysis.
No Conflicts
No conflicts of interest identified
No conflicts of interest were disclosed, and the study appears to be independently conducted with no evidence of industry influence on design, analysis, or publication.
Funders
Independent Analysis Safeguards
- Central adjudication of events by a clinical event committee
- Use of standardized frailty index calculation based on established Rockwood approach
- Statistical analysis performed using established methods with imputation for missing data
The study is a post hoc analysis of the ESPRIT trial, which was funded by public Chinese institutions. No author affiliations with industry or financial ties to pharmaceutical companies are mentioned. The absence of a formal COI statement does not imply undisclosed conflicts, but no evidence of industry influence was found in the text.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
2 videos from Dr Brad Stanfield cite this study, drawing 3 claims from it.
- Very strong evidence
Randomized or controlled trials support this claim, alongside consistent supporting evidence.
Evidence
Authored by
23 researchersIf this is your work, this is how we attribute it on Fit Body Science. Shitian Li is listed as the lead author.
- Chinese Academy of Medical Sciences & Peking Union Medical College
Cited in 3 claims
- Chinese Academy of Medical Sciences & Peking Union Medical College
Cited in 3 claims
- Chinese Academy of Medical Sciences & Peking Union Medical College
Cited in 3 claims
- Chinese Academy of Medical Sciences & Peking Union Medical College
Cited in 3 claims
- Chinese Academy of Medical Sciences & Peking Union Medical College
Cited in 3 claims
- Luoyang Central Hospital Affiliated to Zhengzhou University
Cited in 3 claims
- Chinese Academy of Medical Sciences & Peking Union Medical College
Cited in 3 claims
- Haibo ZhangCorrespondingChinese Academy of Medical Sciences & Peking Union Medical College
Cited in 3 claims
- Jingkuo LiCorrespondingChinese Academy of Medical Sciences & Peking Union Medical College
Cited in 3 claims